LUBAC modulates signalling by various immune receptors. In TNF signalling, linear (also known as M1) ubiquitin enables full gene-activation and prevents cell death. However, the mechanisms underlying cell-death prevention remain ill-defined. We show that LUBAC activity enables TBK1 and IKKε recruitment to and activation at the TNFR1-signalling complex (TNFR1-SC). Whilst exerting only limited effects on TNF-induced gene-activation, TBK1/IKKε are essential to prevent TNF-induced cell death. Mechanistically, TBK1/IKKε phosphorylate RIPK1 in the TNFR1-SC, thereby preventing RIPK1-kinase-activity-dependent cell death. This activity is essential in vivo , as it prevents TNF-induced lethal shock. Strikingly, NEMO/IKKγ, which mostly, but not exclusively, binds to the TNFR1-SC via M1-ubiquitin, mediates recruitment of the adaptors TANK and NAP1/AZI2 which are constitutively associated with TBK1/IKKε and TBK1, respectively. We here discover a previously unrecognised TBK1/IKKε-mediated cell-death checkpoint and uncover an essential survival function for NEMO by enabling recruitment and activation of these noncanonical IKKs to prevent TNF-induced cell death.

The use of nanoparticles in foods, materials, and clinical treatments has increased dramatically in the past decade. Because of the possibility of human exposure to nanoparticles, there is an urgent need to investigate the molecular mechanisms underlying the cellular responses that might be triggered. Such information is necessary to assess potential health risks arising from the use of nanoparticles, and for developing new formulations of next generation nanoparticles for clinical treatments. Using mass spectrometry-based proteomic technologies and complementary techniques (e.g., Western blotting and confocal laser scanning microscopy), we present insights into the silver nanoparticle-protein interaction in the human LoVo cell line. Our data indicate that some unique cellular processes are driven by the size. The 100 nm nanoparticles exerted indirect effects via serine/threonine protein kinase (PAK), mitogen-activated protein kinase (MAPK), and phosphatase 2A pathways, and the 20 nm nanoparticles induced direct effects on cellular stress, including generation of reactive oxygen species and protein carbonylation. In addition, we report that proteins involved in SUMOylation were up-regulated after exposure to 20 nm silver nanoparticles. These results were further substantiated by the observation of silver nanoparticles entering the cells; however, data indicate that this was determined by the size of the nanoparticles, since 20 nm particles entered the cells while 100 nm particles did not.

Acquired resistance to MEK1/2 inhibitors (MEKi) arises through amplification of BRAF V600E or KRAS G13D to reinstate ERK1/2 signalling. Here we show that BRAF V600E amplification and MEKi resistance are reversible following drug withdrawal. Cells with BRAF V600E amplification are addicted to MEKi to maintain a precise level of ERK1/2 signalling that is optimal for cell proliferation and survival, and tumour growth in vivo. Robust ERK1/2 activation following MEKi withdrawal drives a p57 KIP2 -dependent G1 cell cycle arrest and senescence or expression of NOXA and cell death, selecting against those cells with amplified BRAF V600E . p57 KIP2 expression is required for loss of BRAF V600E amplification and reversal of MEKi resistance. Thus, BRAF V600E amplification confers a selective disadvantage during drug withdrawal, validating intermittent dosing to forestall resistance. In contrast, resistance driven by KRAS G13D amplification is not reversible; rather ERK1/2 hyperactivation drives ZEB1-dependent epithelial-to-mesenchymal transition and chemoresistance, arguing strongly against the use of drug holidays in cases of KRAS G13D amplification.

Aims: A recent study conducted in mice reported that liver-specific knockout of tumor suppressor Pten augments nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcriptional activity. Here, we further investigated how phosphatase and tensin homolog deleted on chromosome 10 (PTEN) controls NRF2 and the relevance of this pathway in human carcin ogenesis. Results: Drug and genetic targeting to PTEN and phosphoproteomics approaches indicated that PTEN leads to glycogen synthase kinase-3 (GSK-3)-mediated phosphorylation of NRF2 at residues Ser 335 and Ser 338 and subsequent beta-transducin repeat containing protein (b-TrCP)-dependent but Kelch-like ECH-associated protein 1 (KEAP1)-independent degradation. Rescue experiments in PTEN-deficient cells and xerographs in athymic mice indicated that loss of PTEN leads to increased NRF2 signature which provides a proliferating and tumorigenic advantage. Tissue microarrays from endometrioid carcinomas showed that 80% of PTEN-negative tumors expressed high levels of NRF2 or its target heme oxygenase-1 (HO-1). Innovation: These results uncover a new mechanism of oncogenic activation of NRF2 by loss of its negative regulation by PTEN/GSK-3/b-TrCP that may be relevant to a large number of tumors, including endometrioid carcinomas. Conclusion: Increased activity of NRF2 due to loss of PTEN is instrumental in human carcinogenesis and represents a novel therapeutic target. Antioxid. Redox Signal. 21, 2498-2514.